We rank companies based on fund manager, research analyst and news sentiment
ANL

Adlai Nortye Ltd. American Depositary Shares
ANL

$10.56
4.52%
 

About: Adlai Nortye Ltd is a global clinical-stage biotechnology company focused on the discovery and development of innovative cancer therapies for patients across the spectrum of tumor types. The company has robust pipeline of drug candidates it includes buparlisib (AN2025), palupiprant (AN0025), and AN4005, as well as four preclinical candidates.

Employees: 130

0
Funds holding %
of 6,474 funds
Analysts bullish %
News positive %

Fund manager confidence

Based on 2023 Q4 SEC filings by fund managers ($100M+ AUM)

0% more funds holding

Funds holding: 3 [Q3] → 3 (+0) [Q4]

0% more first-time investments, than exits

New positions opened: 1 | Existing positions closed: 1

0% more repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 1

34% less capital invested

Capital invested by funds: $853K [Q3] → $560K (-$293K) [Q4]

Research analyst outlook

1 Wall Street Analyst provided 1 year price forecasts over the past 6 months

Low target
$30
184%
upside
Avg. target
$30
184%
upside
High target
$30
184%
upside

1 analyst rating

positive
100%
neutral
0%
negative
0%
Cantor Fitzgerald
Louise Chen
184%upside
$30
Overweight
Initiated
24 Oct 2023

Financial journalist opinion